Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > New email from Matthew Perraton

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Mar 22, 2024 10:17am

184 Views

Post# 35946959

RE:RE:RE:New email from Matthew Perraton

Lesalpes29 wrote: Trying to understand is hard. If we look at it since one year or more ... TLT is not giving what is needed to get pre-BTD from FDA. An other delay? Not before when? I'm lost.

Pre-BTD wasn't just getting everything looking pretty for FDA before BTD submission. It also involved getting permission from the patients to use their data. I think. So yeah that is why BTD approval estimate got pressed back into 2nd qtr. I'd be shocked if pre-BTD wasn't already in or very close.

<< Previous

Bullboard Posts

Next >>

What will the U.S. election results mean for Canada?